164 related articles for article (PubMed ID: 25951974)
1. Dominant-negative IKAROS enhances IL-3-stimulated signaling in wild-type but not BCR-ABL1(+) mouse BA/F3 cells.
von Palffy S; Bulaeva E; Babovic S; Kannan N; Knapp DJ; Wei L; Eaves CJ; Beer PA
Exp Hematol; 2015 Jul; 43(7):514-23.e1-2. PubMed ID: 25951974
[TBL] [Abstract][Full Text] [Related]
2. BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells.
Klein F; Feldhahn N; Herzog S; Sprangers M; Mooster JL; Jumaa H; Müschen M
Oncogene; 2006 Feb; 25(7):1118-24. PubMed ID: 16205638
[TBL] [Abstract][Full Text] [Related]
3. IKAROS isoform 6 enhances BCR-ABL1-mediated proliferation of human CD34+ hematopoietic cells on stromal cells.
Suzuki K; Ono R; Ohishi K; Masuya M; Kataoka I; Liu B; Nakamori Y; Ino K; Monma F; Hamada H; Kitamura T; Katayama N; Nosaka T
Int J Oncol; 2012 Jan; 40(1):53-62. PubMed ID: 21901249
[TBL] [Abstract][Full Text] [Related]
4. Targeting of heme oxygenase-1 attenuates the negative impact of Ikaros isoform 6 in adult BCR-ABL1-positive B-ALL.
Lin X; Zou X; Wang Z; Fang Q; Chen S; Huang J; Zhe N; Yu M; Zhang Y; Wang J
Oncotarget; 2016 Aug; 7(33):53679-53701. PubMed ID: 27447561
[TBL] [Abstract][Full Text] [Related]
5. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros.
Mullighan CG; Miller CB; Radtke I; Phillips LA; Dalton J; Ma J; White D; Hughes TP; Le Beau MM; Pui CH; Relling MV; Shurtleff SA; Downing JR
Nature; 2008 May; 453(7191):110-4. PubMed ID: 18408710
[TBL] [Abstract][Full Text] [Related]
6. Dominant-negative Ikaros cooperates with BCR-ABL1 to induce human acute myeloid leukemia in xenografts.
Theocharides AP; Dobson SM; Laurenti E; Notta F; Voisin V; Cheng PY; Yuan JS; Guidos CJ; Minden MD; Mullighan CG; Torlakovic E; Dick JE
Leukemia; 2015 Jan; 29(1):177-87. PubMed ID: 24791856
[TBL] [Abstract][Full Text] [Related]
7. BCR-ABL and constitutively active erythropoietin receptor (cEpoR) activate distinct mechanisms for growth factor-independence and inhibition of apoptosis in Ba/F3 cell line.
Ahmed M; Dusanter-Fourt I; Bernard M; Mayeux P; Hawley RG; Bennardo T; Novault S; Bonnet ML; Gisselbrecht S; Varet B; Turhan AG
Oncogene; 1998 Jan; 16(4):489-96. PubMed ID: 9484838
[TBL] [Abstract][Full Text] [Related]
8. Stage specific over-expression of the dominant negative Ikaros 6 reveals distinct role of Ikaros throughout human B-cell differentiation.
Tonnelle C; Dijon M; Moreau T; Garulli C; Bardin F; Chabannon C
Mol Immunol; 2009 May; 46(8-9):1736-43. PubMed ID: 19285729
[TBL] [Abstract][Full Text] [Related]
9. Ikaros dominant negative isoform (Ik6) induces IL-3-independent survival of murine pro-B lymphocytes by activating JAK-STAT and up-regulating Bcl-xl levels.
Kano G; Morimoto A; Takanashi M; Hibi S; Sugimoto T; Inaba T; Yagi T; Imashuku S
Leuk Lymphoma; 2008 May; 49(5):965-73. PubMed ID: 18464116
[TBL] [Abstract][Full Text] [Related]
10. Illegitimate RAG-mediated recombination events are involved in IKZF1 Δ3-6 deletion in BCR-ABL1 lymphoblastic leukaemia.
Dong Y; Liu F; Wu C; Li S; Zhao X; Zhang P; Jiao J; Yu X; Ji Y; Zhang M
Clin Exp Immunol; 2016 Sep; 185(3):320-31. PubMed ID: 27198500
[TBL] [Abstract][Full Text] [Related]
11. The Ikaros splice isoform, Ikaros 6, immortalizes murine haematopoietic progenitor cells.
Ruiz A; Williams O; Brady HJ
Int J Cancer; 2008 Sep; 123(6):1240-5. PubMed ID: 18623087
[TBL] [Abstract][Full Text] [Related]
12. Genetic analysis of Ikaros target genes and tumor suppressor function in BCR-ABL1
Schjerven H; Ayongaba EF; Aghajanirefah A; McLaughlin J; Cheng D; Geng H; Boyd JR; Eggesbø LM; Lindeman I; Heath JL; Park E; Witte ON; Smale ST; Frietze S; Müschen M
J Exp Med; 2017 Mar; 214(3):793-814. PubMed ID: 28190001
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity of SNX2-ABL1 toward tyrosine kinase inhibitors distinct from that of BCR-ABL1.
Tomita O; Iijima K; Ishibashi T; Osumi T; Kobayashi K; Okita H; Saito M; Mori T; Shimizu T; Kiyokawa N
Leuk Res; 2014 Mar; 38(3):361-70. PubMed ID: 24367893
[TBL] [Abstract][Full Text] [Related]
14. IK6 isoform with associated cytogenetic and molecular abnormalities in Chinese patients with Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
Yao L; Cen J; Chen S; Shen H; Chen Y; He J; Chen Z
Leuk Lymphoma; 2013 Aug; 54(8):1626-32. PubMed ID: 23150929
[TBL] [Abstract][Full Text] [Related]
15. Pim-1 expression is sufficient to induce cytokine independence in murine hematopoietic cells, but is dispensable for BCR-ABL-mediated transformation.
Nosaka T; Kitamura T
Exp Hematol; 2002 Jul; 30(7):697-702. PubMed ID: 12135666
[TBL] [Abstract][Full Text] [Related]
16. IKK-dependent activation of NF-κB contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1.
Hsieh MY; Van Etten RA
Blood; 2014 Apr; 123(15):2401-11. PubMed ID: 24464015
[TBL] [Abstract][Full Text] [Related]
17. Ikaros (IKZF1) alterations and minimal residual disease at day 15 assessed by flow cytometry predict prognosis of childhood BCR/ABL-negative acute lymphoblastic leukemia.
Volejnikova J; Mejstrikova E; Dörge P; Meissner B; Zimmermannova O; Svojgr K; Stanulla M; Cario G; Schrappe M; Stary J; Hrusak O; Trka J; Fronkova E
Pediatr Blood Cancer; 2013 Mar; 60(3):420-7. PubMed ID: 22997141
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line.
Matulonis U; Salgia R; Okuda K; Druker B; Griffin JD
Exp Hematol; 1993 Oct; 21(11):1460-6. PubMed ID: 8405226
[TBL] [Abstract][Full Text] [Related]
19. Disruption of IKAROS activity in primitive chronic-phase CML cells mimics myeloid disease progression.
Beer PA; Knapp DJ; Miller PH; Kannan N; Sloma I; Heel K; Babovic S; Bulaeva E; Rabu G; Terry J; Druker BJ; Loriaux MM; Loeb KR; Radich JP; Erber WN; Eaves CJ
Blood; 2015 Jan; 125(3):504-15. PubMed ID: 25370416
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of the Ikaros 6 isoform is restricted to t(4;11) acute lymphoblastic leukaemia in children and infants and has a role in B-cell survival.
Ruiz A; Jiang J; Kempski H; Brady HJ
Br J Haematol; 2004 Apr; 125(1):31-7. PubMed ID: 15015965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
